Abstracts tagged "interstitial lung disease"

Abstract Number: 2114 • 2017 ACR/ARHP Annual Meeting
Interstitial Pneumonia with Autoimmune Features (IPAF): Are There Definable Subsets?
Sepehr Mesdaghinia¹, Julio Arturo Huapaya², Brainerd Ewarien² and Virginia D. Steen¹, ¹Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ²Medicine, MedStar Georgetown University Hospital, Washington, DC
- Background/Purpose: Interstitial lung disease (ILD) can be an early manifestation of an occult connective tissue disease (CTD). It is important to separate these patients…
Abstract Number: 2150 • 2017 ACR/ARHP Annual Meeting
Serum Microrna-1 Can be a Predictive Marker for Disease Activity of Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Yumiko Sugiyama, Ryusuke Yoshimi, Yosuke Kunishita, Daiga Kishimoto, Yohei Kirino and Hideaki Nakajima, Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Background/Purpose: Although intensive immunosuppressive treatment are necessary for the severe cases with polymyositis (PM)/dermatomyositis (DM), the prognostic factors or disease activity indices for PM/DM have…
Abstract Number: 2151 • 2017 ACR/ARHP Annual Meeting
The Predictive Risk Factors for Opportunistic Infection during Treatment for Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Yumiko Sugiyama^1,2, Ryusuke Yoshimi^1,2, Maasa Tamura^2,3, Naoki Hamada^1,2, Hideto Nagai^1,2, Naomi Tsuchida^1,4, Yosuke Kunishita^1,2, Yutaro Soejima^1,2, Daiga Kishimoto^1,2, Reikou Kamiyama^1,2, Kaoru Minegishi^1,5, Yohei Kirino^1,2, Shigeru Ohno^1,6 and Hideaki Nakajima², ¹Y-CURD Study Group, Yokohama, Japan, ²Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Y-CURD Study Group, Yokohma, Japan, ⁴Department of Hematology and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁵Rheumatic Disease Center, Yokohama City University Medical Center, Yokohama, Japan, ⁶Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Although concomitant infectious diseases are the predominant causes of death in patients with polymyositis (PM)/dermatomyositis (DM)-associated interstitial lung disease (ILD), intensive immunosuppressive treatment are…
Abstract Number: 2160 • 2017 ACR/ARHP Annual Meeting
Clinical Significance of Anti-Aminoacyl tRNA Synthetase Antibodies Which Are Positive By ELISA but Not By Immunoprecipitation – the Variations of Antigen Recognition and the Association with Interstitial Lung Diseases but Not Myositis –
Yuki Ishikawa^1,2, Ran Nakashima¹, Takaki Nojima^3,4, Takuya Isayama⁵, Nobuo Kuramoto¹, Kosaku Murakami¹, Hajime Yoshifuji¹, Koichiro Ohmura¹ and Tsuneyo Mimori¹, ¹Clinical Immunology and Rheumatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²One Joslin Place, Joslin Diabetes Center, Harvard Medical School, Boston, MA, ³Clinical Immunology and Rheumatolog, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Nojima Internal Medicine Clinic, Hiroshima, Japan, ⁵Medical & Biological Laboratories CO.,LTD., Nagoya, Japan
Background/Purpose: Anti-aminoacyl tRNA synthetase (ARS) antibodies are associated with common clinical characters, which are fever, polyarthritis, interstitial lung disease (ILD), Raynaud’s phenomenon, mechanic’s hand and…
Abstract Number: 2173 • 2017 ACR/ARHP Annual Meeting
Characteristics Unique to MDA5 and Anti-Ro/SSA-52 Kda Dual Antibody Positive Patients with Inflammatory Myopathies
Juan J Maya, Olga Pinkston, Florentina Berianu, Benjamin Wang and Andy Abril, Rheumatology, Mayo Clinic Florida, Jacksonville, FL
Background/Purpose: The anti-melanoma differentiation-associated gene 5 antibody (MDA5) was recently classified as a myositis-specific antibody (MSA), and has been associated with rapidly progressive interstitial lung…
Abstract Number: 98 • 2017 ACR/ARHP Annual Meeting
Impact of a Lung Ultrasound Course for Rheumatology Specialist (IMPACT-2)
Christopher Gasho¹, Karina Torralba², David Chooljian³, Cong-Bin Wang⁴ and Vi Dinh⁴, ¹Pulmonary and Critical Care Medicine, Loma Linda Medical Center, 12354 Anderson St, CA, ²Division of Rheumatology, Department of Internal Medicine, Loma Linda University, Loma Linda, CA, ³Loma Linda Veteran Affairs Hospital, Loma Linda, CA, ⁴Loma Linda University Medical Center, Loma Linda, CA
Background/Purpose: Although much emphasis is focused on lung ultrasonography(US) within the critical care field, there is a growing interest in the use of lung…
Abstract Number: 2392 • 2017 ACR/ARHP Annual Meeting
Impact of the Pattern of Interstitial Lung Disease on Mortality in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Namrata Singh¹, Jimmy Varghese², Bryant R. England³, Joshua J. Solomon⁴, Kaleb Michaud⁵, Ted R. Mikuls⁶ and Marin Schweizer⁷, ¹Internal Medicine, University of Iowa Hospitals and Clinics and Iowa City VA, Iowa City, IA, ²Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, ³Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Division of Pulmonary and Critical Care Medicine, National Jewish Health, Denver, CO, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁷Internal Medicine, Iowa City VA, Iowa City, IA
ABSTRACT Impact of the Pattern of Interstitial Lung Disease on Mortality in Rheumatoid Arthritis: A systematic review and meta-analysis Background/Purpose: Interstitial lung disease affects 10-15%…
Abstract Number: 257 • 2017 ACR/ARHP Annual Meeting
The Use of Positron Emission Tomography (PET)-Scan for the Quantitative Assessment of Interstitial Lung Disease in Systemic Sclerosis
Daphne Peelen¹, Ben Zwezerijnen², Esther Nossent¹, Lilian Meijboom¹, Otto Hoekstra³, Conny van der Laken⁴ and Alexandre Voskuyl⁴, ¹VUmc, Amsterdam, Netherlands, ²Nuclear Medicine, VUmc, Amsterdam, Netherlands, ³Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Department of Rheumatology, Amsterdam Rheumatology and immunology Center - location VU University Medical Center, Amsterdam, The Netherlands, Amsterdam, Netherlands
Background/Purpose: Interstitial lung disease (ILD) in systemic sclerosis is treated by immunosuppressive drugs (e.g. cyclophosphamide), aimed at reduction of inflammatory response . Differentiation between inflamed…
Abstract Number: 2402 • 2017 ACR/ARHP Annual Meeting
Rituximab in Rheumatoid Arthritis with Interstitial Lung Disease: A Multicenter Study of 32 Patients
Carlos Fernández-Díaz¹, Delia Reina², Paula Rubio-Muñoz³, Ana Urruticoechea-Arana⁴, María Carrasco-cubero⁵, María Martín-López⁶, Jose A. Miranda-Filloy⁷, Ignacio Villa-Blanco⁸, Ana Milena Millan⁹, Ivan Castellví¹⁰, Olga Maiz-Alonso¹¹, Antonio Juan¹², Fátima Álvarez Reyes¹³, José Luis Martín-Varillas¹, Nuria Vegas-Revenga¹, Ricardo Blanco¹ and Miguel Angel González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ³Rheumatology,, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁴Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ⁵Hospital Infanta Cristina, Badajoz, Spain, ⁶Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Rheumatology Division, Hospital Lucus Augusti, Lugo, Spain, ⁸Hospital de Sierrallana, Sierrallana, Spain, ⁹Unitat de Reumatologia. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ¹¹Hospital Universitario Donostia. San Sebastian. Spain, Donostia, Spain, ¹²Hospital Universitario Son Llàtzer. Rheumatology, Palma de Mallorca, Spain, ¹³Rheumatology, University Hospital Ntra. Sra. de La Candelaria, Santa Cruz de Tenerife, Spain
Background/Purpose: Anti-TNFα drugs and several conventional disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate (MTX) have been involved in the development of Interstitial Lung Disease (ILD).…
Abstract Number: 552 • 2017 ACR/ARHP Annual Meeting
Mast Cells Are Involved in the Pathogenesis of Sjögren Syndrome By Inducing Tissue Fibrosis
Shinjiro Kaieda¹, Kyoko Fujimoto², Masaki Okamoto³, Masaki Tominaga², Tomoaki Hoshino⁴ and Hiroaki Ida⁵, ¹Department of Medicine, *Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine, kurume, Japan, ²Kurume University School of Medicine, Kurume, Japan, ³Medicine, Kurume University School of Medicine, Kurume, Japan, ⁴Department of Medicine, Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan, ⁵Respiorogy, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan
Background/Purpose: Mast cells have been implicated in many immune-inflammatory disorders. They mediate a variety of inflammatory and fibrotic conditions, but their role in sialadenitis and…
Abstract Number: 2412 • 2017 ACR/ARHP Annual Meeting
Mortality and Clinical Features in Rheumatoid Arthritis and Interstitial Lung Disease
Cristina Vadillo Font¹, Maria Asunción Nieto², Leticia Leon³, Luis Rodriguez-Rodriguez⁴, Judit Font Urgelles¹, Esperanza Pato Cour¹, Juan Angel Jover⁵ and Lydia A Alcazar⁶, ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Pneumology. Hospital Clínico San Carlos, MD PhD, Madrid, Spain, ³Rheumatology, Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ⁴Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁵Rheumatology. Hospital Clínico San Carlos, MD PhD, Madrid, Spain, ⁶Rheumatology Department and Heath Research Institute (IdISSC), Hospital Clinico San Carlos, Madrid, Spain
Background/Purpose: Interstitial lung disease (ILD) is the most common extra-articular manifestation in Rheumatoid Arthritis (RA) generating higher mortality in these patients. The objective is to…
Abstract Number: 749 • 2017 ACR/ARHP Annual Meeting
Treatment with Cyclophosphamide for Systemic Sclerosis-Interstitial Lung Disease Does Not Lead to a Sustained Improvement in Lung Function in Two Independent Cohorts
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Myung Sim¹, Ning Li², Dinesh Khanna³, Michael Roth⁴, Philip J. Clements⁴, Anna-Maria Hoffmann-Vold⁵, Daniel E. Furst¹, Grace Kim⁶, Jonathan Goldin¹ and Robert Elashoff⁷, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Biomathematics, University of California, Los Angeles, Los Angeles, CA, ³University of Michigan, Ann Arbor, MI, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵Oslo University Hospital, Oslo, Norway, ⁶Radiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁷University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) after 1 year in Scleroderma…
Abstract Number: 2675 • 2017 ACR/ARHP Annual Meeting
Lung Transplant Trends in Patients’ with Systemic Sclerosis Using UNOS (United Network Organ Sharing) Database from 2000-2014
Osman Bhatty¹, Rouhin Sen¹, Douglas Moore² and Joseph Nahas³, ¹Department of Medicine, CHI Creighton University Medical Center, Omaha, NE, ²Department of Pulmonary/Critical Care, CHI Creighton University Medical Center, Omaha, NE, ³Department of Rheumatology, CHI Creighton University Medical Center, Omaha, NE
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease once characterized by high mortality rates now with better outcomes. Pulmonary disease has overtaken renal failure…
Abstract Number: 861 • 2017 ACR/ARHP Annual Meeting
CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice
Sho Sendo¹, Jun Saegusa¹, Hirotaka Yamada², Yoshihide Ichise², Ikuko Naka³, Yo Ueda², Takaichi Okano², Soshi Takahashi⁴, Kengo Akashi⁵, Akira Onishi⁶ and Akio Morinobu⁴, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁴Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁵Department of Rheumatology and Clinical Immnology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Department for Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
CD11b+Gr1dim tolerogenic Dendritic Cell-like Cells Suppress the Progression of Interstitial Lung Disease in SKG Mice Background/Purpose: SKG mice develop interstitial lung disease (ILD) resembling rheumatoid arthritis-associated…
Abstract Number: 943 • 2017 ACR/ARHP Annual Meeting
The Course of the Forced Vital Capacity during Treatment for Systemic Sclerosis-Related Interstitial Lung Disease Predicts Long-Term Survival in 2 Independent Cohorts
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Myung Sim¹, Dinesh Khanna², Michael Roth³, Philip J. Clements³, Daniel E. Furst¹, Lynette Keyes-Elstein⁴, Ashley Pinckney⁴, Ellen Goldmuntz⁵, Robert Elashoff⁶ and Keith Sullivan⁷, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²University of Michigan, Ann Arbor, MI, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Rho Federal Systems, Inc., Chapel Hill, NC, ⁵NIAID, NIH, Bethesda, MD, ⁶University of California, Los Angeles, Los Angeles, CA, ⁷Duke University, Durham, NC
Background/Purpose: While prior observational studies have identified predictors of mortality in systemic sclerosis-interstitial lung disease (SSc-ILD), no studies have evaluated predictors of long-term mortality in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].